Agent Information
The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
Cemiplimab (REGN2810, Libtayo®) is a humanized, hinge-stabilized, IgG4K monoclonal antibody (mAb) designed to target PD-1-expressing cells, including T cells, and sustain or restore their effector function by blocking checkpoint inhibitory interactions between PD-1 and its ligands (PD-L1 and PD-L2). It has received approval for the treatment of patients with metastatic or some locally advanced cutaneous squamous cell carcinomas.